Novo Nordisk to Broaden Wegovy Access With Vials

Novo Nordisk is preparing to introduce Wegovy vials, expanding access to its blockbuster weight-loss treatment as competition heats up in the obesity drug market.

The company confirmed it is exploring new device formats for Wegovy vials, with some expected to roll out this year and others at a later stage.

Wegovy, a widely prescribed GLP-1 therapy for chronic weight management, is currently available in pre-filled injectable pens. By offering vials, Novo Nordisk aims to provide more flexibility in dosing and potentially improve supply efficiency. The move comes at a time when demand for obesity drugs remains strong but competition is intensifying.

Also Read: India's Innovative Therapies Set Global Standard at Low Cost

The company said it is “exploring various device presentations,” signaling a broader strategy to diversify how the drug is delivered. While specific launch timelines and markets were not disclosed, the plan reflects Novo’s effort to strengthen its position in the fast-growing weight-loss segment.

The decision follows similar steps by rival Eli Lilly, which introduced vial presentations for its competing obesity treatment. Industry analysts view alternative packaging formats as a way to improve patient access and manage manufacturing constraints.

As prescription trends shift and rivals gain ground, Novo Nordisk is moving quickly to protect its market share. With obesity drugs projected to remain a high-growth category, the launch of Wegovy vials could play a key role in shaping the next phase of competition.